4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation

4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation

Although the milestone discovery of immune checkpoint blockade (ICB) has been translated into clinical practice, only a fraction of patients can benefit from it with durable responses and subsequent long-term survival. Here, we tested the anti-tumor effect of combining PD-L1 blockade with 4-1BB cost...

Full description

Bibliographic Details
Main Authors: Qiu-xia Qu, Xin-yun Zhu, Wen-wen Du, Hong-bin Wang, Yu Shen, Yi-bei Zhu, Cheng Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-04-01
Series:Frontiers in Immunology
Subjects:
4-1BB
PD-L1
tissue-resident CD8+ T cell
immunotherapy
mAb
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.00577/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.00577/full

Similar Items